Skip to main content
. 2021 Sep 1;125(10):1377–1387. doi: 10.1038/s41416-021-01528-1

Fig. 6. Apalutamide radio-sensitises PCa cells in vivo.

Fig. 6

Effect of apalutamide or bicalutamide combination with radiotherapy in 22Rv1 prostate cancer xenografts: a, b show the growth rate of xenografts growing in SCID and R2G2 mice, respectively, after radiotherapy and its combination with bicalutamide and two-dose schedules of apalutamide; c shows typical images of R2G2 mice with fluorescent xenografts followed for 14 days after therapy, with the IVIS kinetics system; d, e show typical haematoxylin/eosin xenograft tissue sections after radiotherapy and its combination with bicalutamide and apalutamide, where necrosis is indicated with black arrows.